en Radiation Biology Radiation Biology تحقيق بديع Original Research <div style="text-align: justify;"><span style="font-size:10pt"><span style="text-justify:newspaper"><span style="text-kashida-space:50%"><span style="line-height:119%"><span style="font-family:Calibri"><span style="color:black"><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Background</span></span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-weight:bold"><span style="language:en-US">:</span></span></span></span></span> <span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:black"><span style="language:en-US">In this study, prognostic features of radiation were investigated in cancer patients with 1-10 brain metastases (BM) who have not under surgery and survived longer than 6 months. </span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Materials and Methods</span></span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-weight:bold"><span style="language:en-US">:</span></span></span></span></span> <span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:black"><span style="language:en-US">This retrospective study included 136 patients have lung, breast, colon cancer and malign melanoma (MM) with 1-10 BM. All patients and data of BM patients who lived longer than 6 months radiotherapy (RT) related factors affecting their survival rates were examined. Patients were given only WBRT (Whole brain Radiotherapy) in 8-20 fractions with a 160-300 cGy / day fraction, or WBRT with local boost RT with an additional daily 300-350 cGy fraction. </span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Results</span></span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-weight:bold"><span style="language:en-US">:</span></span></span></span></span> <span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:black"><span style="language:en-US">When the results were evaluated </span></span></span></span><span lang="tr" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:black"><span style="language:tr">analysis showed that the having CT, breast cancer, a KPS of 60% or more, daily fraction dose of RT affected survival significantly in all patients. Then subgroub analysis were obtained according to survival rates, number of metastases more than 5 affects life negatively (r=-0.435 and p=0.03) for survival longer than 6 months (SL6m) and survival shorter or equal than 6 months SS6m. The WBRT doses of 3000 cGy with 300 cGy daily fraction size negatively affected life compared to 2500 cGy with 250 cGy&nbsp; (r=-0.280 and p=0.01). </span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Conclusion</span></span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-weight:bold"><span style="language:en-US">:</span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:black"><span style="language:en-US"> It was determined that KPS > 60 and limiting WBRT doses up to 250 / 2500 cGy daily and total in patients with BM between 1-10 was the important best prognostic factor due to RT for SL6m, which increased patient performance and survival rates.</span></span></span></span></span></span></span></span></span></span></div> SRS, SBRT, Simultaneous Integrated Boost, brain metastasis, TomoTherapy, radiotherapy. 37 44 http://ijrr.com/browse.php?a_code=A-10-1-1002&slc_lang=en&sid=1 H.S. Kızıltan hskiziltan@gmail.com 7900319475328460023075 7900319475328460023075 Yes Health Sciences University, Basaksehir Cam and Sakura City Hospital, Department of Radiation Oncology, Turkeye G. Coban 7900319475328460023076 7900319475328460023076 No Bezmialem Vakif University, Faculty of Medicine. Department of Pathology, PC: 34093, Fatih, Turkeye P. Altınok 7900319475328460023077 7900319475328460023077 No Bezmialem Vakif University, Faculty of Medicine. Department of Radiation Oncology, PC: 34093, Fatih, Turkeye E. Tekce 7900319475328460023078 7900319475328460023078 No Bezmialem Vakif University, Faculty of Medicine. Department of Radiation Oncology, PC: 34093, Fatih, Turkeye A. Mayadagli 7900319475328460023079 7900319475328460023079 No Bezmialem Vakif University, Faculty of Medicine. Department of Radiation Oncology, PC: 34093, Fatih, Turkeye